Probi has signed a long-term agreement with Cilag, a member of the Johnson & Johnson Family of Companies for the development of a probiotic product
The rapid growth of the probiotic segment and new exciting research on the importance of human microbiota have increased the interest from pharma companies, and their consumer health care divisions, in probiotic product development.
Probi has over 25 years experience in the successful development of clinically substantiated, health enhancing probiotics. To further expand Probi's product development pipeline and commercialize its strain portfolio, Probi has signed a long-term development agreement with Cilag GmbH International, a member of the Johnson & Johnson Family of Companies.
The parties will jointly initiate a probiotic development program. The program will be funded under non-disclosed financial terms by Cilag GmbH International and Probi will contribute with probiotic expertise.
“We are very happy to initiate this development program together with a strong global partner in OTC. By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together.” says Ole Søgaard Andersen CEO of Probi.
FOR FURTHER INFORMATION, CONTACT:
Ole Søgaard Andersen CEO, Probi, tel +46 46 286 89 40, e-mail: firstname.lastname@example.org
Linda Neckmar, VP EMEA & APAC, Probi, tel +46 46 286 89 71, e-mail: email@example.com
Niklas Brandt, CIO & Investor relations, Probi, tel +46 46 286 89 26, e-mail: firstname.lastname@example.org
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com.